Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Xencor regains rights to XmAb-5871

Oct. 29, 2014

Philogen begins phase II study of F8-IL10

Oct. 29, 2014

Ablynx reports results from subcutaneous ALX-0061 bioavailability study

Oct. 24, 2014

Phase III trials of secukinumab in ankylosing spondylitis meet primary endpoint

Oct. 23, 2014

FDA approves Xiaflex to treat up to two joints in Dupuytren's contracture

Oct. 21, 2014

Ampio Pharmaceuticals provides update on multiple-injection studies of Ampion

Oct. 20, 2014

Idera's IMO-9200 moves into phase I development

Oct. 16, 2014

Mochida and LG Life Sciences enter adalimumab biosimilar agreement

Oct. 15, 2014

Merck Sharp & Dohme designs new tyrosine-protein kinase inhibitors

Oct. 15, 2014

Merck & Co. divulges new JAK inhibitors

Oct. 13, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...